Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
LNTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$56.06 - $126.89
Previous CloseN/A
Volume177.90K
Average Volume (3M)788.87K
Market Cap
$5.80B
Enterprise Value$7.77B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)13.5
Beta0.23
Next Earnings
Feb 26, 2025EPS Estimate
1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.02
Shares Outstanding69,526,840
10 Day Avg. Volume855,657
30 Day Avg. Volume788,871
Standard Deviation0.17
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)8.30
P/FCF Ratio12.90
Enterprise Value/Market Cap1.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.96
Enterprise Value/Ebitda11.92
Forecast
1Y Price Target
$132.86Price Target Upside63.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Lantheus News
PremiumCompany Announcements
Lantheus Appoints Dr. Morrow to Board of Directors
PremiumCompany Announcements
Lantheus to Acquire Evergreen Theragnostics for $250 Million---
Bulls Say, Bears Say
Bulls Say
Financial Performance3Q24 total revenue of $378.7M beat consensus of $371.7M and estimate of $374.9M.
Strategic AcquisitionsLantheus' acquisition of Evergreen Theragnostics represents a strategically compelling move on the radiopharma infrastructure & clinical development side that further solidifies their position as a 'fully integrated' radiopharmaceutical leader.
Bears Say
Earnings ProjectionsAnalysts view '25 as more of a 'transition year' for EPS, indicating short-term challenges due to dilution from recent acquisitions.
---
Ownership Overview
2.11% Insiders
37.42% Mutual Funds
2.45% Other Institutional Investors
31.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $56.06 and its highest was $126.89 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $5.80B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Feb 26, 2025 which is in 5 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Nov 06, 2024. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.556 by $0.144.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.55.
How many shares outstanding does Lantheus have?
Lantheus has 69,526,840 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.7 in its last earnings report, beating expectations of $1.556. Following the earnings report the stock price went down -20.694%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
---
Lantheus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$132.86 (63.24% Upside)
$132.86 (63.24% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 10.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.64%
12-Months-Change
Fundamentals
Return on Equity
45.53%
Trailing 12-Months
Asset Growth
34.70%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
---
LNTH Company Deck
---
LNTH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in flagship products like PYLARIFY and DEFINITY, boosted by strategic initiatives and positive regulatory developments. However, these were slightly tempered by sequential revenue declines and challenges with clinical trials for PNT2002. Overall, the financial performance and strategic advancements support a positive outlook.Read More>---
LNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
---
LNTH Stock 12 Month Forecast
Average Price Target
$132.86
▲(63.24% Upside)
Technical Analysis
Best Analysts Covering LNTH
1 Year
1 Year Success Rate
19/29 ratings generated profit
1 Year Average Return
+50.54%
reiterated a buy rating 23 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +50.54% per trade.
---